Distributor inventory
Voglibose 0.3 mg + Metformin (strength unknown)
Type 2 diabetes mellitus (adjunct to diet and exercise) to improve glycaemic control, especially post‑meal blood glucose; used when control is inadequate with single therapy.
Voglibose is an alpha‑glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, reducing post‑prandial glucose spikes. Metformin decreases hepatic glucose production and improves insulin sensitivity, thereby lowering fasting and overall blood glucose.
Oral tablet. Take exactly as prescribed. Typically taken with meals: voglibose is taken just before/with the first bite of food; metformin is usually taken with food to reduce stomach upset. Swallow whole with water; do not crush/chew unless advised.
Common side effects of VOGLIFIN M 0.3 may include:
Prescription medicine. Risk of hypoglycaemia increases when used with insulin or sulfonylureas (may need dose adjustment). Metformin may rarely cause lactic acidosis—risk higher with kidney impairment, dehydration, severe infection, alcohol use, liver disease, heart failure, or hypoxia; stop and seek care if fast breathing, severe weakness, abdominal pain, or drowsiness occur. Monitor kidney function before and during therapy; avoid in severe renal impairment. Temporarily stop metformin before/after iodinated contrast imaging or major surgery as advised by a doctor. Use caution in elderly and in vitamin B12 deficiency (long‑term metformin can reduce B12).
